Klain M, Maurea S, Cuocolo A, Colao A, Marzano L, Lombardi G, Salvatore M
Medicina Nucleare, Centro di Studio per la Medicina Nucleare del Consiglio Nazionale delle Ricerche (CNR), Università degli Studi Federico II, Napoli, Italy.
Eur J Nucl Med. 1996 Dec;23(12):1568-74. doi: 10.1007/BF01249618.
Technetium-99m tetrofosmin is a lipophilic phosphine used for myocardial perfusion imaging. Biodistribution studies have shown significant thyroid uptake of tetrofosmin and preliminary reports have suggested that tetrofosmin imaging may be of value in patients with thyroid cancer. In this study, tetrofosmin whole-body scintigraphy was performed in 35 patients with evidence of thyroid diseases. All patients underwent laboratory evaluation of thyroid function as well as 99mTc pertechnetate scan, thallium-201 (n=16) 99mTc-methoxyisobutylisonitrile (MIBI) (n=19) whole-body studies. Thyroid images were semi-quantitatively analysed by a 4-point score: 0=no significant uptake; 1=uptake increased as compared to background activity, but inferior to normal thyroid tissue; 2=uptake equal to normal thyroid tissue; 3=uptake superior to normal thyroid tissue. Pathology examinations were obtained. A total of 41 thyroid nodules were detected, of which 15 were goitre nodules, 13 adenomas and 13 malignant lesions. In goitre nodules, concordant results of tetrofosmin and pertechnetate uptake (score 1 or 0) were observed in the majority of lesions (87%). In function adenomas (n=10), both tetrofosmin uptake and pertechnetate uptake were score 3. In non-function adenomas (n=3), tetrofosmin uptake was score 3, while pertechnetate uptake was score 0. In six malignant lesions, tetrofosmin uptake was score 3, while pertechnetate uptake was score 0; in the other seven lesions, where a prevalence of goitre abnormalities was observed, results of tetrofosmin and pertechnetate uptake were similar (score 0 or 1). In seven (70%) of the ten patients with malignant nodules, whole-body tetrofosmin images showed increased abnormal uptake in a total of 28 extra-thyroid tumour sites, as subsequently confirmed by other techniques. When tetrofosmin images were compared to 201Tl and 99mTc-MIBI scans, concordant results were observed in all cases. In conclusion, tetrofosmin imaging may be particularly useful to characterize and stage patients with malignant thyroid nodules; it shows similar results to thallium but provides better image quality. Comparable findings were observed between tetrofosmin and MIBI studies. Thus, tetrofosmin may be an alternative to thallium and MIBI in the aforementioned patients.
锝-99m替曲膦是一种用于心肌灌注显像的亲脂性膦。生物分布研究显示替曲膦在甲状腺有显著摄取,初步报告表明替曲膦显像对甲状腺癌患者可能有价值。在本研究中,对35例有甲状腺疾病证据的患者进行了替曲膦全身闪烁显像。所有患者均接受了甲状腺功能实验室评估以及高锝酸盐扫描、201铊(n = 16)、99m锝-甲氧基异丁基异腈(MIBI)(n = 19)全身检查。甲状腺图像通过4分制进行半定量分析:0分=无明显摄取;1分=摄取较本底活性增加,但低于正常甲状腺组织;2分=摄取等于正常甲状腺组织;3分=摄取高于正常甲状腺组织。获取了病理检查结果。共检测到41个甲状腺结节,其中15个为甲状腺肿结节、13个为腺瘤和13个为恶性病变。在甲状腺肿结节中,大多数病变(87%)的替曲膦和高锝酸盐摄取结果一致(1分或0分)。在功能性腺瘤(n = 10)中,替曲膦摄取和高锝酸盐摄取均为3分。在非功能性腺瘤(n = 3)中,替曲膦摄取为3分,而高锝酸盐摄取为0分。在6个恶性病变中,替曲膦摄取为3分,而高锝酸盐摄取为0分;在其他7个观察到甲状腺肿异常占优势的病变中,替曲膦和高锝酸盐摄取结果相似(0分或1分)。在10例有恶性结节的患者中,7例(70%)的全身替曲膦图像显示共有28个甲状腺外肿瘤部位的异常摄取增加,随后经其他技术证实。当将替曲膦图像与201铊和99m锝-MIBI扫描进行比较时,所有病例结果均一致。总之,替曲膦显像对于恶性甲状腺结节患者的特征描述和分期可能特别有用;其结果与铊相似,但图像质量更好。替曲膦和MIBI研究观察到类似的结果。因此,在上述患者中,替曲膦可能是铊和MIBI的替代物。